Crown Laboratories Acquires Xycrobe Therapeutics, Inc.
May 22, 2019
Crown Laboratories, a privately held skin care company based in Johnson City, Tennessee, has acquired Xycrobe Therapeutics, a developer of skin microbiome-based biotherapeutic technology. Crown plans to integrate Xycrobe’s microbiome platform and scientific team into its R&D organization to expand therapeutic and consumer skin-care capabilities; financial terms were not disclosed.
- Buyers
- Crown Laboratories, Inc.
- Targets
- Xycrobe Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Trilogy Laboratories Acquires YNS Cosmeceuticals
July 2, 2026
Healthcare Services
Trilogy Laboratories announced the acquisition of YNS Cosmeceuticals, a skincare brand known for a simplified approach to effective daily routines. The deal is intended to combine YNS’s established skincare philosophy with Trilogy’s pharmaceutical formulation expertise, FDA-registered cosmetic manufacturing capabilities, and physician leadership.
-
Mapmygenome Acquires Microbiome Insights
May 29, 2025
Biotechnology
Mapmygenome, an AI-driven genomics company based in Hyderabad, India, has acquired Microbiome Insights, a Canadian microbiome sequencing and bioinformatics CRO with a CAP-accredited lab. The deal expands Mapmygenome's capabilities in metagenomics and bioinformatics and accelerates its geographic expansion into North America; financial terms were not disclosed.
-
Crown Laboratories Acquires Revance Therapeutics in $924M Merger
August 12, 2024
Healthcare Services
Crown Laboratories, Inc. entered into a merger agreement to acquire Revance Therapeutics, Inc. for $6.66 per share in cash, representing an enterprise value of $924 million. The deal closed after Crown commenced a tender offer and then completed a second-step merger, with Revance becoming wholly owned by Crown and delisted from Nasdaq.
-
Crown Laboratories Acquires Eclipse Medcorp's Aesthetics Assets
May 24, 2022
Medical Devices
Crown Laboratories has acquired the global, aesthetics-focused assets of Eclipse Medcorp, LLC, expanding Crown's aesthetics product portfolio and integrating Eclipse's devices into its Aesthetics business unit. The deal aims to broaden Crown's product offerings to aesthetics providers domestically and internationally and preserve service and medical-education support for Eclipse customers under Crown.
-
Crown Laboratories Acquires StriVectin from L Catterton
August 26, 2021
Consumer Products
Crown Laboratories, a Hildred Capital portfolio company, has entered into a definitive agreement to acquire StriVectin from L Catterton. StriVectin will operate as a wholly owned subsidiary within Crown's new Premium Skincare Division, with its president Cori Aleardi joining Crown's executive team; the deal was expected to close by mid-September 2021.
-
Crown Laboratories Acquires Keri Brand from GlaxoSmithKline
May 1, 2019
Consumer Products
Crown Laboratories acquired the North American rights to the Keri skin care brand from GlaxoSmithKline and concurrently received an equity investment from Greenspring Associates. Existing investors Hildred Capital Partners and Montreux Equity Partners provided financing in connection with the transaction; financial terms were not disclosed.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.